Current share price

Background

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSULĀ®) to treat Osteoarthritis (OA) – a market with over 31m sufferers in the USA alone.

More details about our programme can be found here.

Current shareholders click here to access and update your personal details.